These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38067159)

  • 41. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang Z; Sun K; Zhu ZM; Zhang P; Yang J; Yang SW; Zheng MQ
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2941-2948. PubMed ID: 33877657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
    Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
    Reid JH; Marini BL; Nachar VR; Brown AM; Devata S; Perissinotti AJ
    Crit Rev Oncol Hematol; 2020 Apr; 148():102897. PubMed ID: 32109715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.
    Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D
    Front Immunol; 2021; 12():756583. PubMed ID: 35095839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced stages of classical Hodgkin lymphoma - first-line treatment options.
    Mociková H
    Klin Onkol; 2021; 34(6):450-454. PubMed ID: 34911330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
    Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
    Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
    Liu-Kreyche P; Shen H; Marino AM; Iyer RA; Humphreys WG; Lai Y
    Front Pharmacol; 2019; 10():749. PubMed ID: 31379564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence-Based Minireview: What is the optimal timing of anti-PD-1 antibodies in relapsed classical Hodgkin lymphoma?
    Allen PB; LaCasce AS
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):249-251. PubMed ID: 31808863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
    Tien FM; Tsai CH; Liu JH; Lin CT
    J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA
    J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
    Kumar A; Casulo C; Yahalom J; Schöder H; Barr PM; Caron P; Chiu A; Constine LS; Drullinsky P; Friedberg JW; Gerecitano JF; Hamilton A; Hamlin PA; Horwitz SM; Jacob AG; Matasar MJ; McArthur GN; McCall SJ; Moskowitz AJ; Noy A; Palomba ML; Portlock CS; Straus DJ; VanderEls N; Verwys SL; Yang J; Younes A; Zelenetz AD; Zhang Z; Moskowitz CH
    Blood; 2016 Sep; 128(11):1458-64. PubMed ID: 27458003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Plattel WJ; Bergamasco A; Trinchese F; Gavini F; Bent-Ennakhil N; Zomas A; Castillon G; Arredondo-Bisono T; Cristarella T; Moride Y; von Tresckow B
    Leuk Lymphoma; 2021 Dec; 62(14):3320-3332. PubMed ID: 34323643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
    Stamatoullas A; Ghesquières H; Feugier P; André M; Le Bras F; Gac AC; Borel C; Gastinne T; Quittet P; Morschhauser F; Ribrag V; Guidez S; Nicolas-Virelizier E; Berriolo-Riedinger A; Vander Borght T; Edeline V; Brice P
    Leuk Lymphoma; 2022 Dec; 63(13):3063-3071. PubMed ID: 35975738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How I incorporate novel agents into the treatment of classical Hodgkin lymphoma.
    Epperla N; Herrera AF
    Blood; 2021 Aug; 138(7):520-530. PubMed ID: 33889927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequencing therapies in Hodgkin lymphoma.
    Phillips EH; Collins GP; Cwynarski K
    Lancet Haematol; 2021 Aug; 8(8):e537-e539. PubMed ID: 34329571
    [No Abstract]   [Full Text] [Related]  

  • 58. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
    Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
    Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk-adapted therapy for advanced-stage Hodgkin lymphoma.
    Spinner MA; Advani RH
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):200-206. PubMed ID: 30504311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
    Ishizawa K; Yanai T
    Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.